Merck is snapping up a private biotech focused on genetically defined neurodegenerative disorders and rare diseases, promising to pay $610 million if everything works out.
Caraway Therapeutics, based in Cambridge, MA, is developing a slate of preclinical small molecule therapeutics “that boost cellular clearance pathways to restore balance” — with…
Click here to view original post
